(NASDAQ: EVAX) Evaxion A's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.52%.
Evaxion A's earnings in 2026 is -$8,655,000.On average, 6 Wall Street analysts forecast EVAX's earnings for 2026 to be -$239,614,380, with the lowest EVAX earnings forecast at -$657,959,571, and the highest EVAX earnings forecast at -$17,514,452. On average, 6 Wall Street analysts forecast EVAX's earnings for 2027 to be -$463,632,559, with the lowest EVAX earnings forecast at -$751,953,795, and the highest EVAX earnings forecast at -$13,135,839.
In 2028, EVAX is forecast to generate -$255,210,583 in earnings, with the lowest earnings forecast at -$478,144,533 and the highest earnings forecast at -$13,135,839.